Literature DB >> 33155074

Higher Edmonton Obesity Staging System scores are independently associated with postoperative complications and mortality following bariatric surgery: an analysis of the MBSAQIP.

Samuel L Skulsky1, Jerry T Dang2, Noah J Switzer2, Arya M Sharma3, Shahzeer Karmali2, Daniel W Birch2.   

Abstract

INTRODUCTION: Bariatric surgery is an evidence-based approach for sustained weight loss in patients with severe obesity. The most common procedures in North America are the laparoscopic sleeve gastrectomy (LSG) and laparoscopic Roux-en-Y gastric bypass (LRYGB). The Edmonton Obesity Staging System (EOSS) is a tool that assigns patients a score of 0 to 4 according to their obesity-related comorbidities and functional status. Previous research demonstrates that increasing EOSS score is associated with overall non-operative mortality risk.
OBJECTIVE: We sought to assess the association of the EOSS with major 30-day postoperative complications following LSG or LRYGB.
METHODS: Primary LSG or LRYGB patients were identified from the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program data registry. Patients were assigned EOSS scores according to their comorbidities and functional limitations extracted from the database. Multivariable logistic regression analysis was conducted to evaluate the relationship between EOSS score, age, sex, BMI, type of procedure, or operative time with 30-day major complications.
RESULTS: From 2015 to 2017, 430,238 patients (79.4% female) who underwent primary LSG or LRYGB were identified. The relative frequencies of patients by EOSS score were: 0 and 1 (23.9%), 2 (62.8%), 3 (10.5%), and 4 (2.9%). Mean preoperative BMI was 45.4 (SD 7.9) kg/m2 and mean age was 44.6 (SD 12.0) years. The overall 30-day major complication rate was 3.5%. EOSS 2, 3, and 4 were significantly associated with major complications. The strongest associations with major complications were EOSS 4 (OR 2.30; 95% CI 2.11-2.51, p < 0.001) and LRYGB versus LSG (OR 2.03; 95% CI 1.97-2.11, p < 0.001). EOSS 3 and 4 were most strongly associated with death.
CONCLUSION: Higher EOSS scores are independently associated with 30-day major postoperative complications and mortality. The EOSS provides utility in staging patients and identifying those at greater risk of postoperative complications.
© 2020. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Edmonton obesity staging system; LRYGB; LSG; Postoperative complications

Mesh:

Year:  2020        PMID: 33155074     DOI: 10.1007/s00464-020-08138-7

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  16 in total

1.  Edmonton Obesity Staging System: association with weight history and mortality risk.

Authors:  Jennifer L Kuk; Chris I Ardern; Timothy S Church; Arya M Sharma; Raj Padwal; Xuemei Sui; Steven N Blair
Journal:  Appl Physiol Nutr Metab       Date:  2011-08-14       Impact factor: 2.665

2.  Hypertension and obesity comorbidities increases coronary risk, affects domains of sexual function and sexual quality of life.

Authors:  H Alidu; W K B A Owiredu; N Amidu; C K Gyasi-Sarpong; P P M Dapare; A T Bawah; C Obirikorang; A T Luuse
Journal:  Int J Impot Res       Date:  2017-11-27       Impact factor: 2.896

3.  Bands and bypasses: 30-day morbidity and mortality of bariatric surgical procedures as assessed by prospective, multi-center, risk-adjusted ACS-NSQIP data.

Authors:  Robert T Lancaster; Matthew M Hutter
Journal:  Surg Endosc       Date:  2008-09-20       Impact factor: 4.584

4.  The obesity paradox: body mass index and outcomes in patients undergoing nonbariatric general surgery.

Authors:  John T Mullen; Donald W Moorman; Daniel L Davenport
Journal:  Ann Surg       Date:  2009-07       Impact factor: 12.969

5.  Reply to Letter to the Editor "Left Gastric Artery Embolization for Weight Loss-a Dead-End Procedure".

Authors:  Luigi Angrisani; A Santonicola; A Vitiello; L Ferraro; P Iovino
Journal:  Obes Surg       Date:  2018-11       Impact factor: 4.129

6.  Higher Edmonton Obesity Staging System scores are associated with complications following laparoscopic Roux-en-Y gastric bypass.

Authors:  Samuel L Skulsky; Jerry T Dang; Adrian Battiston; Noah J Switzer; Daniel W Birch; Arya M Sharma; Shahzeer Karmali
Journal:  Surg Endosc       Date:  2019-08-27       Impact factor: 4.584

7.  Weight and Metabolic Outcomes 12 Years after Gastric Bypass.

Authors:  Ted D Adams; Lance E Davidson; Sheldon E Litwin; Jaewhan Kim; Ronette L Kolotkin; M Nazeem Nanjee; Jonathan M Gutierrez; Sara J Frogley; Anna R Ibele; Eliot A Brinton; Paul N Hopkins; Rodrick McKinlay; Steven C Simper; Steven C Hunt
Journal:  N Engl J Med       Date:  2017-09-21       Impact factor: 91.245

8.  Obesity and quality of life: mediating effects of pain and comorbidities.

Authors:  Moonseong Heo; David B Allison; Myles S Faith; Shankuan Zhu; Kevin R Fontaine
Journal:  Obes Res       Date:  2003-02

9.  Assessment of postdischarge complications after bariatric surgery: A National Surgical Quality Improvement Program analysis.

Authors:  Sophia Y Chen; Miloslawa Stem; Michael A Schweitzer; Thomas H Magnuson; Anne O Lidor
Journal:  Surgery       Date:  2015-06-19       Impact factor: 3.982

10.  The importance of the Edmonton Obesity Staging System in predicting postoperative outcome and 30-day mortality after metabolic surgery.

Authors:  Sonja Chiappetta; Christine Stier; Simone Squillante; Sophia Theodoridou; Rudolf A Weiner
Journal:  Surg Obes Relat Dis       Date:  2016-03-02       Impact factor: 4.734

View more
  2 in total

Review 1.  Preoperative preparation and premedication of bariatric surgical patient.

Authors:  Marina Varbanova; Brittany Maggard; Rainer Lenhardt
Journal:  Saudi J Anaesth       Date:  2022-06-20

2.  The Edmonton Obesity Staging System and pregnancy outcomes in women with overweight or obesity: A secondary analysis of a randomized controlled trial.

Authors:  Sarah Louise Killeen; Cara A Yelverton; Aisling A Geraghty; Maria A Kennelly; Shane Eakins; Lily Farrell; Jillian F Fagan; John Mehegan; Fionnuala M McAuliffe
Journal:  Clin Obes       Date:  2022-02-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.